{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06270706",
            "orgStudyIdInfo": {
                "id": "PLN-101095-ONC-101"
            },
            "organization": {
                "fullName": "Pliant Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors",
            "officialTitle": "A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-phase-study-of-pln-in-adults-with-advanced-or-metastatic-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-01-26",
            "studyFirstSubmitQcDate": "2024-02-13",
            "studyFirstPostDateStruct": {
                "date": "2024-02-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-12",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pliant Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab (the study treatment regimen) in adult participants with advanced or metastatic solid tumors for which pembrolizumab is indicated but have documented disease progression (refractory \\[primary resistance\\]) or relapsed \\[secondary resistance\\]) after at least 3 months from the start of treatment with pembrolizumab.\n\nThe study will consist of 2 main parts:\n\n* Part 1: Consecutive dose-escalation cohorts using a Bayesian optimal interval (BOIN) dose escalation design\n* Part 2: Dose-expansion cohorts using Simon's 2-stage design"
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Solid Tumor"
            ],
            "keywords": [
                "Advanced Solid Tumors Cancer",
                "Head and Neck Squamous Cell Cancer",
                "Colorectal Cancer",
                "Urothelial Carcinoma",
                "Gastro-esophageal Junction Cancers",
                "Esophageal Cancer",
                "Cervical Cancer",
                "Hepatocellular Carcinoma",
                "Renal Cell Carcinoma",
                "Endometrial Cancer",
                "Cutaneous Squamous Cell Carcinoma",
                "Triple Negative Breast Cancer",
                "Melanoma",
                "Non-Squamous Cell Lung Cancer"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 77,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1 Dose Escalation: PLN-101095 given as monotherapy and in combination with Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: PLN-101095",
                        "Drug: Pembrolizumab"
                    ]
                },
                {
                    "label": "Part 2 Dose Expansion: PLN-101095 in combination with Pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: PLN-101095",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PLN-101095",
                    "description": "PLN-101095",
                    "armGroupLabels": [
                        "Part 1 Dose Escalation: PLN-101095 given as monotherapy and in combination with Pembrolizumab",
                        "Part 2 Dose Expansion: PLN-101095 in combination with Pembrolizumab"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Pembrolizumab",
                    "armGroupLabels": [
                        "Part 1 Dose Escalation: PLN-101095 given as monotherapy and in combination with Pembrolizumab",
                        "Part 2 Dose Expansion: PLN-101095 in combination with Pembrolizumab"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Proportion of participants with treatment-emergent adverse events and serious adverse events per CTCAE Version 5.0.",
                    "timeFrame": "Signing ICF until 16 weeks after end of study treatment regimen"
                },
                {
                    "measure": "Number of participants with a Dose Limiting Toxicity (DLT) defined as toxicities that meet predefined severity criteria, assess as having a suspected relationship to study drug, unrelated to disease, inter-current illness, or concomitant medications.",
                    "timeFrame": "First dose to 35 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum observed plasma concentration (Cmax) to characterize the plasma pharmacokinetics (PK).",
                    "timeFrame": "First dose until 10 weeks"
                },
                {
                    "measure": "Time to maximum observed concentration (Tmax) to characterize the plasma pharmacokinetics (PK).",
                    "timeFrame": "First dose until 10 weeks"
                },
                {
                    "measure": "Area under the concentration-time curve over a dosing interval (AUC0-\u03c4) to characterize the plasma pharmacokinetics (PK).",
                    "timeFrame": "First dose until 10 weeks"
                },
                {
                    "measure": "Disease control rate (DCR) is defined by the proportion of participants who maintain disease control (iCR, iPR or iSD) per iRECIST Version 1.1.",
                    "timeFrame": "Day 1 until end of study treatment regimen"
                },
                {
                    "measure": "Objective response rate (ORR) is defined by the proportion of participants with an iCR or iPR per iRECIST Version 1.1.",
                    "timeFrame": "Day 1 until end of study treatment regimen"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Has histologically or cytologically confirmed advanced solid tumor\n2. Has an advanced or metastatic solid tumor (for which pembrolizumab is indicated) and have evidence of disease progression after treatment with pembrolizumab.\n3. At least 1 measurable lesion, as defined by RECIST v1.1\n4. Estimated survival of \u22653 months\n5. No effective therapeutic options available (eg, has received standard of care or is intolerant of, refuses, or is not eligible for standard of care antineoplastic therapy)\n\nExclusion Criteria:\n\n1. Any immune-related medical conditions that would put participants at greater risk when receiving pembrolizumab\n2. Previous treatment with pembrolizumab \\<21 days prior to the first dose of combination therapy of pembrolizumab and PLN-101095\n3. Received an immunotherapy other than pembrolizumab in the last 4 weeks prior to the first dose of PLN-101095\n4. Received radiotherapy (RT) within 1 week for palliative bone-directed therapy and 4 weeks for all other types, prior to the first dose of PLN-101095\n5. Received chemotherapy or other targeted therapies within 2 weeks prior to the first dose of PLN-101095\n6. Received a cell therapy within the last 12 months prior to the first dose of PLN-101095\n7. Known active central nervous system (CNS) metastases (brain and/or leptomeningeal metastases)\n8. Pregnant or lactating female participant",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Pliant Therapeutics Medical Monitor",
                    "role": "CONTACT",
                    "phone": "clintrials@pliantrx.com",
                    "email": "clintrials@pliantrx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Pliant Therapeutics Medical Monitor",
                    "affiliation": "Pliant Therapeutics, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Yale University",
                    "status": "RECRUITING",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06511",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics (START)",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "NEXT Austin",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M20559",
                    "name": "Disease Progression",
                    "relevance": "LOW"
                },
                {
                    "id": "M9613",
                    "name": "Carcinoma, Hepatocellular",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5548",
                    "name": "Carcinoma, Renal Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M11528",
                    "name": "Melanoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T4906",
                    "name": "Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T1341",
                    "name": "Clear Cell Renal Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}